Evidation Insights from 165,000 People Show Continued Growth Potential Amid Uneven Adoption in the GLP-1 Market

Among 119,000 surveyed individuals actively trying to lose weight, 24% had ever used prescription medication for weight management and 15% had ever used a GLP-1, suggesting significant room for continued market growth as adoption varies by age, gender, and income.

SAN MATEO, Calif.--(BUSINESS WIRE)--Evidation, the leader in direct-from-participant real-world data and health research, today announced new insights from multiple, longitudinal surveys showing that the market for GLP-1s and prescription weight management is growing rapidly, but unevenly, across demographic subpopulations including age, gender, and income. The insights point to a highly segmented market, where access, affordability, awareness, and treatment pathways may shape who starts treatment and who stays on it over time.

Among 119,000 people who report that they are actively trying to lose weight, only 15% reported ever trying a GLP-1, underscoring the scale of the population still outside of prescription treatment pathways. These insights also show higher levels of GLP-1 experience, defined as current or prior use, among adults ages 40-59, women, and higher-income respondents, reinforcing that the market is segmented and that treatment pathways may differ by population.

Since July 2024, Evidation has been conducting ongoing, direct-from-participant research with a cohort of more than 165,000 individuals who have shared information about their weight-management and cardiometabolic health experiences to understand emerging trends and behaviors in treatment, condition management, and care experiences over time, including individuals’ experiences with GLP-1s.

“The GLP-1 market is growing quickly, but we're still in the early stages of understanding how people actually navigate treatment," said Leslie Wilberforce, CEO of Evidation. "Our data show that experiences differ widely across populations, and factors like access, affordability, awareness, and personal preferences all matter. By following people over time, Evidation helps uncover why people start treatment, why they don't, and what supports better long-term outcomes.”

Additional insights from data collected between July 2024 and May 2026 include:

• Among respondents, GLP-1s accounted for nearly all growth in reported use of prescription weight-management medication between May 2025 and May 2026, with GLP-1 experience rising from 9% to 12%.
• Among individuals actively trying to lose weight, 76% reported no lifetime use of prescription weight-management medication.
• Of those actively trying to lose weight without prior use of prescription weight-management medication, 76% had a BMI of 25 or higher and 39% had a BMI of 30 or higher.
• Adults ages 40-49 and 50-59 reported the highest levels of GLP-1 experience, at 17% and 19%, respectively, as of May 2026.
• GLP-1 experience among women reached 15% compared with 9% among men, despite similar mean BMI among respondents with no prior use of prescription weight-management medication.
• GLP-1 experience was highest among respondents with household income of $150,000 or more at 17% and lowest among those with household income under $25,000 at 9%.

Organizations interested in deeper insight into GLP-1 experience, weight-management behaviors, or specific patient populations can contact [e-mail] to discuss available data, on-demand analyses, and population-level insights.

About Evidation’s Cardiometabolic Health and Weight Management Cohort

Evidation’s Cardiometabolic Health and Weight Management Cohort includes more than 165,000 individuals contributing longitudinal real-world data, including detailed experiences with anti-obesity medications, weight-management strategies, and related health conditions. The cohort integrates patient-reported outcomes, continuous digital measures, and permissioned clinical data, and reflects a broad distribution of BMI profiles and cardiometabolic comorbidities. Existing longitudinal data can be augmented with prospective data collection to address emerging evidence needs.

About Evidation

Evidation is redefining real-world data through direct, interactive relationships with millions of individuals. Through continuous engagement, Evidation captures longitudinal data to provide a more complete picture of health, including patient-reported and functional outcomes, connected device data, permissioned clinical records, and biosamples. Its privacy-first platform supports a right person, right time approach to data collection, enabling faster research, stronger evidence, and better product decisions. Founded in 2012, Evidation is headquartered in California.